Ranking All 20 Diabetes Drugs by Efficiency: GLP-1 Peptides Dominate the Top Spots
A benchmarking analysis of 20 FDA-approved diabetes drugs found that the three most efficient were all GLP-1 peptides — oral semaglutide, injectable semaglutide, and dulaglutide.
Quick Facts
What This Study Found
Oral semaglutide, subcutaneous semaglutide, and dulaglutide achieved the highest medication efficiency scores among 20 T2D drugs, while lixisenatide and liraglutide scored lower despite being in the same GLP-1 class.
Key Numbers
Analysis covers tens of FDA-approved diabetes drugs from the 1950s through present day.
How They Did This
Data envelopment analysis (DEA) model using FDA data and meta-analysis results. Evaluated 20 T2D drugs on benefits (glucose lowering, weight loss) and harms (mortality) relative to dosing frequency. Used directional distance function to handle multidimensional outcomes.
Why This Research Matters
With 20+ diabetes drug options, understanding which ones deliver the most benefit per dose helps both patients and clinicians make better treatment decisions. The dominance of GLP-1 peptides confirms their position as the most effective modern diabetes drug class.
The Bigger Picture
The diabetes treatment landscape has fundamentally shifted. Drugs approved before 2010 focused narrowly on blood sugar, while modern GLP-1 peptides deliver glucose control, weight loss, and cardiovascular protection in a single weekly (or daily oral) dose. This efficiency analysis quantifies that paradigm shift and demonstrates why GLP-1 drugs have become the standard of care.
What This Study Doesn't Tell Us
DEA efficiency models involve methodological choices about input/output weighting. Newer drugs have less long-term safety data. Analysis does not account for cost, which is a major real-world treatment factor. Some drugs serve different clinical niches that simple efficiency rankings may not capture.
Questions This Raises
- ?Would including cost data change the efficiency rankings, given the high price of GLP-1 drugs?
- ?How would newer drugs like tirzepatide rank in this framework?
- ?Why do some GLP-1 drugs (lixisenatide, liraglutide) score lower than others despite targeting the same receptor?
Trust & Context
- Key Stat:
- Top 3 are all GLP-1 Oral semaglutide, injectable semaglutide, and dulaglutide achieved maximum medication efficiency among 20 FDA-approved diabetes drugs
- Evidence Grade:
- Moderate evidence: novel analytical approach using FDA data and meta-analysis results, but methodology involves modeling assumptions and does not replace clinical trial comparisons.
- Study Age:
- Published in 2024. Covers the full history of FDA-approved diabetes drugs from the 1950s through present.
- Original Title:
- Benchmarking the medication efficiency and technological progress of diabetes drugs.
- Published In:
- Frontiers in public health, 12, 1396832 (2024)
- Authors:
- Zhang, Hongwei, Wang, Chen(3), Xu, Ting, Liu, Lin, Ban, Xuyan, Liu, Weijie, Yan, Chenli, Han, Xiaodong
- Database ID:
- RPEP-09636
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Why are GLP-1 drugs more efficient than older diabetes medications?
GLP-1 peptides provide three benefits simultaneously: strong blood sugar reduction, significant weight loss, and cardiovascular protection — often with just one weekly injection. Older drugs typically only lower blood sugar and may require multiple daily doses.
Are all GLP-1 drugs equally effective?
No. This analysis found that oral and injectable semaglutide and dulaglutide were the most efficient, while lixisenatide and liraglutide scored lower. Within the GLP-1 class, there are meaningful differences in potency, weight loss, and dosing convenience.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09636APA
Zhang, Hongwei; Wang, Chen; Xu, Ting; Liu, Lin; Ban, Xuyan; Liu, Weijie; Yan, Chenli; Han, Xiaodong. (2024). Benchmarking the medication efficiency and technological progress of diabetes drugs.. Frontiers in public health, 12, 1396832. https://doi.org/10.3389/fpubh.2024.1396832
MLA
Zhang, Hongwei, et al. "Benchmarking the medication efficiency and technological progress of diabetes drugs.." Frontiers in public health, 2024. https://doi.org/10.3389/fpubh.2024.1396832
RethinkPeptides
RethinkPeptides Research Database. "Benchmarking the medication efficiency and technological pro..." RPEP-09636. Retrieved from https://rethinkpeptides.com/research/zhang-2024-benchmarking-the-medication-efficiency
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.